Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and extended follow-up is required to determine the role of ctDNA as a phylogenetic biomarker of relapse in early-stage non-small-cell lung cancer (NSCLC). Here we developed ctDNA methods tracking a median of 200 mutations identified in resected NSCLC tissue across 1,069 plasma samples collected from 197 patients enrolled in the TRACERx study2. A lack of preoperative ctDNA detection distinguished biologically indolent lung adenocarcinoma with good clinical outcome. Postoperative plasma analyses were interpreted within the context of standard-of-care radiological surveillance and administration of cytotoxic adjuvant therapy. Landmark analyses of plasma samples collected within 120 days after surgery revealed ctDNA detection in 25% of patients, including 49% of all patients who experienced clinical relapse; 3 to 6 monthly ctDNA surveillance identified impending disease relapse in an additional 20% of landmark-negative patients. We developed a bioinformatic tool (ECLIPSE) for non-invasive tracking of subclonal architecture at low ctDNA levels. ECLIPSE identified patients with polyclonal metastatic dissemination, which was associated with a poor clinical outcome. By measuring subclone cancer cell fractions in preoperative plasma, we found that subclones seeding future metastases were significantly more expanded compared with non-metastatic subclones. Our findings will support (neo)adjuvant trial advances and provide insights into the process of metastatic dissemination using low-ctDNA-level liquid biopsy. Measurements of subclonal expansion of ctDNA in the plasma before surgery may enable the prediction of future metastatic subclones, offering the possibility for early intervention in patients with non-small-cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Extended Figure 1 TRACERx ctDNA cohort sequencing parameters. A. Stacked bar plot of patient specific panels (PSPs) designed from primary tumour sequencing data showing the number of clonal (dark red) and subclonal (light red) variants per panel. Variants lacking clonality information are displayed in grey (median of 3 variants per patient [1-20], these mutations are either no longer called by TRACERx or called by ArcherDx but not TRACERx, see methods). A median of 126 clonal variants (range 21 to 195) and 64 subclonal variants (range 0 to 174) were tracked by the PSPs. Clonality was determined by PyClone analyses of multi-region exome data derived from primary resections of NSCLC (methods), in the absence of PyClone data, variants present in all multi-region sequenced tumour samples were called clonal. B. Violin plot demonstrating the % of subclonal clusters derived from multi-region tumour exome data tracked by PSPs on a per patient basis. A median of 88% of the subclonal mutation clusters present in each patient's multi-region exome derived phylogenetic tree were tracked [range 0-100]. 184 tumours with phylogenetic trees were included. C. Distribution of cfDNA input values for the cohort, median input of 23ng, n=1069 samples. Capping at 60ng input was performed for some of the cohort explaining the peak at this value; for the remainder of the cohort, all cfDNA extracted was input into the assay (colours represent different cfDNA input categories as indicated). D. Histogram demonstrating the distribution of per-variant unique sequencing depth values across the cohort; unique depth refers to error-controlled depth achieved across a position targeted by a PSP (at least 5 unique molecular identifier (UMI) matched reads required to create a consensus error-controlled read, see methods). The median unique depth per-variant tracked by a PSP was 2226x (range 0 to 53789x, n=201910). E. Correlation between cfDNA input (ng, Y axis) into the assay and the median UMI-corrected depth achieved across a PSP across 1069 plasma timepoints (X axis). Spearman's R value = 0.63 and two-sided P value < 2.2e-16. F. Association between median deduplication ratio achieved in a sample (Y-axis) and cfDNA input into the assay (ng, X-axis); duplication ratio refers to the median number of duplicate UMI-supported reads within a read family. Resequencing of samples where the median duplication ratio was less than 10 was performed where possible to maximise recoverable information from cfDNA samples, given that 5 UMI-supported reads are required to make a UMI family. 17 of 1069 evaluated cfDNA samples exhibited a final median deduplication ratio less than 5 (corresponds to the horizontal line on the plot). Colours correspond to different cfDNA input categories and match panel ©. G-H. Boxplots demonstrating the error rates (%, Y axis) per each of 96 mutation trinucleotide contexts (X axis, 192 mutation trinucleotide contexts [TNCs] simplified to 96 reverse-complement identical mutation types), plots divided by transition event (G) and transversion event (H). Background position data from n=1069 cell-free DNA libraries utilised to generate plots, variants predicted to exhibit low background error rates from pilot data analyses were prioritised for PSP design. Hinges correspond to first and third quartiles, whiskers extend to the largest/smallest value no further than 1.5x the interquartile range. Centre lines represent medians.](https://figures.cochat.ai/paper-figures/eb44e23defae41c3a51b0b861117d71d/tracking-early-lung-cancer-metastatic-dissemination-in-tracerx-using-ctdna-figure-1.jpg)



![Extended Figure 5 Exploration of unexpected MRD positive results in non-relapse patients. A. Table demonstrating details of unexpected ctDNA positive results in patients who did not suffer disease recurrence. B. CRUK0498 false positive analysis: Dot-plots represent confidently detected variants at illustrated cfDNA sampling timepoints (left panel), variants confidently detected in normal tissue, control DNA, and peripheral-blood mononuclear cell (PBMC, buffy-coat) DNA based on application of CRUK0498's patient specific panel to these respective samples (middle panel) and the mutant allele frequencies of selected variants in tumour tissue exome data (right panel). The four variants in the legend (variants in genes ATP2C1, DDIT4L, EYS, and TUSC3) represent variants confidently called at 50% or more of the timepoints across the cfDNA samples (note that confidently called means an individual variant Poisson one-sided P value of <0.01 [generated by MRD caller, see methods]). C. A haematoxylin and eosin image from patient CRUK0498's tumour where exome analysis detected the variants in genes ATP2C1, DDIT4L, EYS at high variant allele-frequencies. This image shows a dense lymphocyte aggregate in this tumour region. Scale bar below image. A single image was analysed. D. A further 19 preoperative PBMC samples were analysed from TRACERx patients; no confident panel-wide variant DNA calls were made in these patients' PBMC samples using the MRD calling algorithm. E. Variant-level analyses of the preoperative samples analysed in panel (D) highlighted that 12 of 3621 variants interrogated by the panels were detected (variant level one-sided Poisson P value <0.01). 8 of 12 detected variants were removed from the MRD caller algorithm in cell-free DNA analyses (cfDNA) due to triggering filters highlighted in the heatmap annotation. Only 2 of the 4 remaining variants carried deep alternate reads in the respective patients' preoperative cfDNA sample (red arrows). The heatmap shows the cfDNA variant allele frequency and the WBC variant allele frequency of the detected variants (grey colour represents no detection of the variant). Two mistargeted germline variants are highlighted by black arrows for patient CRUK0296, variants were targeted in error by the industry panel design pipeline but not by the TRACERx exome pipeline (methods), and were filtered from the MRD calling algorithm due to triggering the outlier filter (dao imbalance filter, dark red).](https://figures.cochat.ai/paper-figures/9fc1e99ff759418c9796cd482e0817a2/tracking-early-lung-cancer-metastatic-dissemination-in-tracerx-using-ctdna-figure-5.jpg)
![Extended Figure 6 Expanded postoperative ctDNA and imaging surveillance analysis. A. Analysis of 13 patients who experienced intracranial relapse who were positive for ctDNA in a postoperative blood sample. The X axis shows the clonal ctDNA level at the point of postoperative ctDNA detection and the Y axis shows the day of postoperative ctDNA detection. Points are coloured based on whether the intracranial relapse was solitary (green), accompanied by another extracranial site (red), or unconfirmed solitary (blue, no extracranial imaging performed) and are shaped by landmark ctDNA status. B. Heatmap of clonal mutation ctDNA level data at first postoperative ctDNA detection. The annotation rows show the landmark ctDNA status of the patient (landmark positive, ctDNA detected within 120 days postoperatively; landmark negative, ctDNA negative within 120 days postoperatively; unevaluable, landmark status cannot be established), the day ctDNA was detected postoperatively, the histology of the primary tumour, and lead time (days from ctDNA detection to clinical relapse). Where lead time was not applicable (for example incompletely resected disease, ctDNA detected post-relapse, see methods) lead time is coloured grey. The next two rows (bar charts) demonstrate the number of clonal or subclonal mutations tracked by an AMP patient-specific panel (PSP); if the bar is blue, it represents confident detection of an individual variant (based on an individual variant P value of <0.01 [one sided Poisson test based on MRD caller output, see methods]), if the bar is black, it represents absence of confident calling of a variant, if the bar is red, it represents that a variant was filtered by the MRD calling algorithm. The final row represents the mean clonal ctDNA level at the first ctDNA detection time point for a patient. This is on a log-10 scale as displayed in the heatmap legend. For patient CRUK0296, ctDNA detection occurred but clonal ctDNA levels were 0% (grey bar) as the mutation driving ctDNA detection postoperatively did not have a clonal status. C Longitudinal per-patient plots in 12 patients who were ctDNA positive prior to adjuvant therapy. Plots are annotated with lead time (L-t), scans performed, and treatment administered (see legend). The Y axis represents clonal ctDNA levels and each circle on the plot represents a blood sampling time point. If the circle is red, it indicates that the blood sample was positive for ctDNA using the MRD caller. The X axis displays days post-surgery. D-E. Kaplan-Meier curves in the landmark evaluable population (patients who donated blood within 120 days post-surgery before treatment or clinical recurrence, n=102/108 landmark evaluable patients were evaluable for survival analysis, see methods for exclusions) showing overall survival (OS,D) or freedom from recurrence (FFR,E) outcomes for landmark positive (dark red) versus landmark negative (grey) patients. Log-rank P values displayed on curves. F. Boxplots showing the distribution of lead times (times from ctDNA detection to clinical recurrence) categorised by patient landmark ctDNA status. Hinges correspond to first and third quartiles, whiskers extend to the largest/smallest value no further than 1.5x the interquartile range. Centre lines represent medians. Kruskal-Wallis test P=0.0057, unadjusted pairwise Wilcoxon-tests compare individual categories, n=63 patients analysed. G. Pie charts demonstrate the number of occurrences of specified ctDNA detection statuses (red – ctDNA negative, green – ctDNA positive, blue – no ctDNA status established), preceding a scan showing no new changes (left) or new equivocal extracranial changes (middle). The ctDNA positive and negative categories are then broken down further into a patient-level analysis showing the outcomes of patients who experienced the occurrence of the specified imaging and ctDNA status event(s). H. Barchart showing the count of specific equivocal anatomical sites noted on scans showing new equivocal changes; equivocal lung lesions and lymph nodes were the most common abnormal equivocal findings on NSCLC surveillance imaging. Multiple equivocal sites can be observed on one scan. I. Barplot of eventual site of relapse and ctDNA status in 33 patients with ctDNA status established prior to surveillance imaging, showing new equivocal lymph node enlargement. The X axis shows the patient ctDNA detection status preceding surveillance scans. The Y axis shows the patient count. Patient CRUK0090 exhibited occurrences of both negative and positive ctDNA statuses prior to separate equivocal lymphadenopathy scans, so is present in both ctDNA positive and negative categories. Other patients are only included once. Patient CRUK0234 was diagnosed with an unresected lymph node, was ctDNA negative postoperatively and included in the analysis. The barcharts are filled with recurrence status of patients in these categories. Recurred with LN refers to lymph node involvement at relapse (dark red colour). Recurred with no LN refers to recurrence with no lymph node involvement (green colour).](https://figures.cochat.ai/paper-figures/5670ab9869b2488ab58fdf6393da00a8/tracking-early-lung-cancer-metastatic-dissemination-in-tracerx-using-ctdna-figure-6.jpg)









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tumor-informed assays, based on the mutations existing in the tumor tissue, enable deep sequencing targeting known mutations and MRD detection, which has been validated across multiple solid tumors.19, 20, 21”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4_9 · Cited by 12,516
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Research works printed but not linked: 2
- Wiesweg M survivalAnalysis: High-Level Interface for Survival Analysis and Associated Plots 2022 Preprint at https://CRAN.R-project.org/package=survivalAnalysis
- Kassambara A Kosinski M Biecek P survminer: Drawing Survival Curves using ‘ggplot2’ 2021 Preprint at https://CRAN.R-project.org/package=survminer
Cited by
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
Self-citationEmbracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Self-citationCirculating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Bartolomucci, A., Nobrega, M., Ferrier, T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 247
The evolution of non-small cell lung cancer metastases in TRACERx
Al Bakir, M., Huebner, A., Martínez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., Moore, D. A., Veeriah, S., Ward, S., Laycock, J., et al. (2023) · Nature · doi:10.1038/s41586-023-05729-x · Cited by 251
Self-citationThe two sides of chromosomal instability: drivers and brakes in cancer
Hosea, R., Hillary, S., Naqvi, S., Wu, S., & Kasim, V. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01767-7 · Cited by 189
Metadata
- Authors
- Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., Weiss, J., Schroeder, M. R., Ward, S., Grigoriadis, K., Shahpurwalla, A., Litchfield, K., Puttick, C., Biswas, D., Karasaki, T., Black, J. R. M., Martínez-Ruiz, C., Bakir, M. A., Pich, O., Watkins, T. B. K., Lim, E. L., Huebner, A., Moore, D. A., Godin-Heymann, N., L’Hernault, A., Bye, H., Odell, A., Kalavakur, P., Gomes, F., Patel, A. J., Manzano, E., Hiley, C. T., Carey, N., Riley, J., Cook, D. E., Hodgson, D., Stetson, D., Barrett, J. C., Kortlever, R. M., Evan, G. I., Hackshaw, A., Daber, R. D., Shaw, J. A., Aerts, H. J. W. L., Licon, A., Stahl, J., Jamal-Hanjani, M., TRACERx Consortium, Lester, J. F., Bajaj, A., Nakas, A., Sodha-Ramdeen, A., Ang, K., Tufail, M., Chowdhry, M. F., Scotland, M., Boyles, R., Rathinam, S., Wilson, C., Marrone, D., Dulloo, S., Fennell, D. A., Matharu, G., Primrose, L., Boleti, E., Cheyne, H., Khalil, M., Richardson, S., Cruickshank, T., Price, G., Kerr, K. M., Benafif, S., Gilbert, K., Naidu, B., Osman, A., Lacson, C., Langman, G., Shackleford, H., Djearaman, M., Kadiri, S., Middleton, G., Leek, A., Hodgkinson, J. D., Totten, N., Montero, A., Smith, E., Fontaine, E., Granato, F., Doran, H., Novasio, J., Rammohan, K., Joseph, L., Bishop, P., Shah, R., Moss, S., Joshi, V., Crosbie, P., Brown, K., Carter, M., Chaturvedi, A., Priest, L., Oliveira, P., Lindsay, C. R., Blackhall, F. H., Krebs, M. G., Summers, Y., Clipson, A., Tugwood, J., Kerr, A., Rothwell, D. G., Kilgour, E., Dive, C., Schwarz, R. F., Kaufmann, T. L., Wilson, G. A., Rosenthal, R., Van Loo, P., Szallasi, Z., Sokac, M., Salgado, R., Diossy, M., Demeulemeester, J., Bunkum, A., Stewart, A., Magness, A., Rowan, A., Karamani, A., Toncheva, A., Chain, B., Campbell, B. B., Castignani, C., Bailey, C., Weeden, C. E., Lee, C., Richard, C., Naceur-Lombardelli, C., Pearce, D. R., Karagianni, D., Levi, D., Hoxha, E., Larose Cadieux, E., Colliver, E., Nye, E., Grönroos, E., Gálvez-Cancino, F., Athanasopoulou, F., Gimeno-Valiente, F., Kassiotis, G., Stavrou, G., Mastrokalos, G., Zhai, H., Lowe, H. L., Matos, I., Goldman, J., Reading, J. L., Herrero, J., Rane, J. K., Nicod, J., Lam, J. M., Hartley, J. A., Peggs, K. S., Enfield, K. S. S., Selvaraju, K., Thol, K., Ng, K. W., Chen, K., Dijkstra, K., Thakkar, K., Ensell, L., Shah, M., Vasquez, M., Litovchenko, M., Werner Sunderland, M., Hill, M. S., Dietzen, M., Leung, M., Escudero, M., Angelova, M., Tanić, M., Sivakumar, M., Kanu, N., Chervova, O., Lucas, O., Al-Sawaf, O., Prymas, P., Hobson, P., Pawlik, P., Stone, R. K., Bentham, R., Hynds, R. E., Vendramin, R., Saghafinia, S., López, S., Gamble, S., Ung, S. K. A., Quezada, S. A., Vanloo, S., Zaccaria, S., Hessey, S., Boeing, S., Beck, S., Bola, S. K., Denner, T., Marafioti, T., Mourikis, T. P., Spanswick, V., Barbè, V., Lu, W.-T., Hill, W., Liu, W. K., Wu, Y., Naito, Y., Ramsden, Z., Veiga, C., Royle, G., Collins-Fekete, C.-A., Fraioli, F., Ashford, P., Clark, T., Forster, M. D., Lee, S. M., Borg, E., Falzon, M., Papadatos-Pastos, D., Wilson, J., Ahmad, T., Procter, A. J., Ahmed, A., Taylor, M. N., Nair, A., Lawrence, D., Patrini, D., Navani, N., Thakrar, R. M., Janes, S. M., Martinoni Hoogenboom, E., Monk, F., Holding, J. W., Choudhary, J., Bhakhri, K., Scarci, M., Hayward, M., Panagiotopoulos, N., Gorman, P., Khiroya, R., Stephens, R. C., Wong, Y. N. S., Bandula, S., Sharp, A., Smith, S., Gower, N., Dhanda, H. K., Chan, K., Pilotti, C., Leslie, R., Grapa, A., Zhang, H., AbdulJabbar, K., Pan, X., Yuan, Y., Chuter, D., MacKenzie, M., Chee, S., Alzetani, A., Cave, J., Scarlett, L., Richards, J., Ingram, P., Austin, S., Lim, E., De Sousa, P., Jordan, S., Rice, A., Raubenheimer, H., Bhayani, H., Ambrose, L., Devaraj, A., Chavan, H., Begum, S., Buderi, S. I., Kaniu, D., Malima, M., Booth, S., Nicholson, A. G., Fernandes, N., Shah, P., Proli, C., Hewish, M., Danson, S., Shackcloth, M. J., Robinson, L., Russell, P., Blyth, K. G., Dick, C., Le Quesne, J., Kirk, A., Asif, M., Bilancia, R., Kostoulas, N., Thomas, M., Birkbak, N. J., McGranahan, N., & Swanton, C.
- Affiliations
- Cancer Research UK (GB)
- The Francis Crick Institute (GB)
- Invitae (United States) (US)
- University College London (GB)
- Brigham and Women's Hospital (US)
- University College Hospital (GB)
- AstraZeneca (United Kingdom) (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of Leicester (GB)
- AstraZeneca (United States) (US)
- University of Cambridge (GB)
- Swansea Bay University Health Board (GB)
- University Hospitals of Leicester NHS Trust (GB)
- Royal Free London NHS Foundation Trust (GB)
- Aberdeen Royal Infirmary (GB)
- University of Aberdeen (GB)
- Whittington Hospital (GB)
- University of Birmingham (GB)
- Cancer Research UK Manchester Centre (GB)
- Manchester University NHS Foundation Trust (GB)
- University of Manchester (GB)
- The Christie NHS Foundation Trust (GB)
- University of Cologne (DE)
- Max Delbrück Center (DE)
- Peter MacCallum Cancer Centre (AU)
- The Netherlands Cancer Institute (NL)
- Institute of Structural and Molecular Biology (GB)
- Institute of Cancer Research (GB)
- The University of Texas MD Anderson Cancer Center (US)
- University Hospital Southampton NHS Foundation Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Royal Surrey County Hospital (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Liverpool Heart and Chest Hospital (GB)
- Princess Alexandra Hospital NHS Trust (GB)
- Cancer Research UK Scotland Institute (GB)
- NHS Greater Glasgow and Clyde (GB)
- Golden Jubilee National Hospital (GB)
- Aarhus University (DK)
- Corresponding author
- Abbosh, Christopher
- McGranahan, Nicholas
- Swanton, Charles
- ORCID
- Abbosh, Christopher
- Frankell, Alexander M.
- Veeriah, Selvaraju
- Chaunzwa, Tafadzwa L.
- Ward, Sophia
- Grigoriadis, Kristiana
- Litchfield, Kevin
- Puttick, Clare
- Biswas, Dhruva
- Karasaki, Takahiro
- Black, James R. M.
- Martínez-Ruiz, Carlos
- Bakir, Maise Al
- Pich, Oriol
- Watkins, Thomas B. K.
- Lim, Emilia L.
- Huebner, Ariana
- Moore, David A.
- Godin-Heymann, Nadia
- Odell, Aaron
- Patel, Akshay J.
- Hiley, Crispin T.
- Carey, Nicolas
- Cook, Daniel E.
- Hodgson, Darren
- Stetson, Daniel
- Barrett, J. Carl
- Kortlever, Roderik M.
- Evan, Gerard I.
- Hackshaw, Allan
- Shaw, Jacqui A.
- Aerts, Hugo J. W. L.
- Jamal-Hanjani, Mariam
- Lester, Jason F.
- Bajaj, Amrita
- Nakas, Apostolos
- Rathinam, Sridhar
- Wilson, Claire
- Marrone, Domenic
- Fennell, Dean A.
- Primrose, Lindsay
- Price, Gillian
- Benafif, Sarah
- Naidu, Babu
- Osman, Aya
- Djearaman, Madava
- Middleton, Gary
- Shah, Rajesh
- Moss, Stuart
- Crosbie, Philip
- Brown, Kate
- Carter, Mathew
- Chaturvedi, Anshuman
- Priest, Lynsey
- Oliveira, Pedro
- Lindsay, Colin R.
- Blackhall, Fiona H.
- Krebs, Matthew G.
- Summers, Yvonne
- Clipson, Alexandra
- Kerr, Alastair
- Rothwell, Dominic G.
- Dive, Caroline
- Schwarz, Roland F.
- Kaufmann, Tom L.
- Wilson, Gareth A.
- Rosenthal, Rachel
- Salgado, Roberto
- Demeulemeester, Jonas
- Bunkum, Abigail
- Magness, Alastair
- Rowan, Andrew
- Chain, Benny
- Castignani, Carla
- Bailey, Chris
- Weeden, Clare E.
- Lee, Claudia
- Richard, Corentin
- Pearce, David R.
- Karagianni, Despoina
- Levi, Dina
- Colliver, Emma
- Nye, Emma
- Gimeno-Valiente, Francisco
- Kassiotis, George
- Stavrou, Georgia
- Lowe, Helen L.
- Matos, Ignacio
- Goldman, Jacki
- Reading, James L.
- Herrero, Javier
- Rane, Jayant K.
- Lam, Jie Min
- Hartley, John A.
- Peggs, Karl S.
- Enfield, Katey S. S.
- Thol, Kerstin
- Ng, Kevin W.
- Chen, Kezhong
- Dijkstra, Krijn
- Thakkar, Krupa
- Ensell, Leah
- Litovchenko, Maria
- Hill, Mark S.
- Dietzen, Michelle
- Leung, Michelle
- Escudero, Mickael
- Angelova, Mihaela
- Tanić, Miljana
- Sivakumar, Monica
- Kanu, Nnennaya
- Chervova, Olga
- Lucas, Olivia
- Hobson, Philip
- Pawlik, Piotr
- Bentham, Robert
- Hynds, Robert E.
- Vendramin, Roberto
- Saghafinia, Sadegh
- López, Saioa
- Ung, Seng Kuong Anakin
- Quezada, Sergio A.
- Zaccaria, Simone
- Hessey, Sonya
- Boeing, Stefan
- Beck, Stephan
- Bola, Supreet Kaur
- Marafioti, Teresa
- Mourikis, Thanos P.
- Barbè, Vittorio
- Lu, Wei-Ting
- Hill, William
- Liu, Wing Kin
- Wu, Yin
- Naito, Yutaka
- Veiga, Catarina
- Royle, Gary
- Fraioli, Francesco
- Ashford, Paul
- Forster, Martin D.
- Lee, Siow Ming
- Borg, Elaine
- Falzon, Mary
- Wilson, James
- Procter, Alexander James
- Nair, Arjun
- Lawrence, David
- Patrini, Davide
- Navani, Neal
- Thakrar, Ricky M.
- Janes, Sam M.
- Scarci, Marco
- Panagiotopoulos, Nikolaos
- Stephens, Robert CM.
- Wong, Yien Ning Sophia
- Bandula, Steve
- Sharp, Abigail
- Smith, Sean
- Dhanda, Harjot Kaur
- Zhang, Hanyun
- AbdulJabbar, Khalid
- Pan, Xiaoxi
- Yuan, Yinyin
- Chee, Serena
- Alzetani, Aiman
- Cave, Judith
- Lim, Eric
- Rice, Alexandra
- Devaraj, Anand
- Begum, Sofina
- Nicholson, Andrew G.
- Fernandes, Nadia
- Danson, Sarah
- Shackcloth, Michael J.
- Kirk, Alan
- Bilancia, Rocco
- Thomas, Mathew
- Birkbak, Nicolai J.
- McGranahan, Nicholas
- Swanton, Charles
- Venue
- Nature
- Published
- 2023-04-13
- Volume
- 616
- Issue
- 7957
- Pages
- 553-562
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7614605
- OpenAlex
- W4365484830
- Cited by
- 382
- References
- 59
- Citations by year
- 2026: 111 · 2025: 126 · 2024: 109 · 2023: 36
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- American Association for Cancer Research (SU2C-AACR-DT23-17)
- Breast Cancer Research Foundation (SU2C-AACR-DT23-17, BCRF-22-157, EDDPMA-Nov21/100034)
- LUNGevity Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca (U01CA209414)
- GlaxoSmithKline
- Melanoma Research Alliance
- International Association for the Study of Lung Cancer
- Aarhus Universitet
- Wellcome Trust (CC2041, 211179/Z/18/Z)
- Francis Crick Institute (CC2088, CC1064, CC2008, CC1119, CC1061, CC1062, CC1107, CC2041)
- LifeArc
- Astex Pharmaceuticals
- Mark Foundation For Cancer Research (21-029-ASP)
- Invitae
- Cancer Research UK (25349, C11496 / A17786, C7893/A26233, RCCCDF- Nov21\100005, A15953, C11496/A30025, CTRNBC-2022/100001, EDDPMA‐Nov21/100034, C416/A21999, EDDCPGM\\100002, A17786, C416/, 24956, A29210, ID16584, 21999, 17786, C444/A15953, CC2041, RCCFEL\100099, 29569, S_3609, 30025)
- National Institute for Health and Care Research (C444/A15953, CL-2015-18-009)
- Foulkes Foundation
- University College London (UCL/12/0279, 13/LO/1546)
- European Commission (HORIZON2020, FP7-PEOPLE-2013, 607722, 835297)
- Rosetrees Trust (PGL21 10119, ID16584, A2437, CF-2021-2 117)
- Aarhus Universitets Forskningsfond (NNF21OC0071483, R272-2017-4040, AUFF-E-2018-7-14)
- Lundbeckfonden (NNF21OC0071483, AUFF-E-2018-7-14, R272‐2017‐4040)
- Novo Nordisk
- University College London Hospitals NHS Foundation Trust
- Novo Nordisk Fonden (16584, ID 16584, NNF21OC0071483)
- Ono Pharmaceutical
- H. Lundbeck A/S
- National Institutes of Health (R35CA22052)
- Genentech
- Stand Up To Cancer (SU2C-AACRDT23-17, AACR-DT23-17)
- Medical Research Council (MR/V033077/1, MR/W025051/1, CC2041)
- Japan Society for the Promotion of Science (052004, 2018-7)
- National Cancer Institute (U01CA190234, R35CA22052, U24CA194354, U01CA209414)
- H2020 European Research Council (866504)
- FP7 Ideas: European Research Council (294851)
- FP7 People: Marie-Curie Actions (607722, FP7-PEOPLE-2013)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- circulating tumor DNA, early-stage non-small cell lung cancer, lung adenocarcinoma, metastasis, liquid biopsy, subclonal expansion, recurrence prediction, adjuvant therapy
- MeSH terms
- Liquid Biopsy, Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Neoplasm Metastasis, Neoplasm Recurrence, Local, Phylogeny, Biomarkers, Tumor, Cohort Studies, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. https://app.cochat.ai/papers/10.1038/s41586-023-05776-4
- The paper
- Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., Weiss, J., Schroeder, M. R., Ward, S., Grigoriadis, K., Shahpurwalla, A., Litchfield, K., Puttick, C., Biswas, D., Karasaki, T., . . . Swanton, C. (2023). Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. https://doi.org/10.1038/s41586-023-05776-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.